Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
KRYS Stock Forecast 2026-2027
$301.00
Current Price
$8.87B
Market Cap
Buy 10
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to KRYS Price Targets
+32.6%
To High Target of $399.00
+3.0%
To Median Target of $310.00
-19.9%
To Low Target of $241.00
KRYS Price Momentum
-2.6%
1 Week Change
+1.4%
1 Month Change
+119.8%
1 Year Change
+22.1%
Year-to-Date Change
-5.8%
From 52W High of $319.48
+135.2%
From 52W Low of $127.99
📊 TOP ANALYST CALLS
Did KRYS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Krystal Biotech is one of their latest high-conviction picks.
Latest KRYS Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, KRYS has a bullish consensus with a median price target of $310.00 (ranging from $241.00 to $399.00). The overall analyst rating is Strong Buy (9.6/10). Currently trading at $301.00, the median forecast implies a 3.0% upside. This outlook is supported by 10 Buy, 1 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
KRYS Analyst Ratings
10
Buy
1
Hold
0
Sell
KRYS Price Target Range
Low
$241.00
Average
$310.00
High
$399.00
Current: $301.00
Latest KRYS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for KRYS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 1, 2026 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $310.00 |
| May 22, 2026 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 18, 2026 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 5, 2026 | Citigroup | Buy | Maintains | $N/A | |
| May 5, 2026 | Evercore ISI Group | Outperform | Maintains | $N/A | |
| May 4, 2026 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 27, 2026 | Wolfe Research | Peer Perform | Initiates | $N/A | |
| Feb 25, 2026 | Guggenheim | Buy | Maintains | $N/A | |
| Feb 18, 2026 | Citigroup | Buy | Maintains | $N/A | |
| Feb 18, 2026 | Chardan Capital | Buy | Maintains | $N/A | |
| Feb 17, 2026 | Jefferies | Buy | Maintains | $N/A | |
| Feb 2, 2026 | Goldman Sachs | Buy | Maintains | $N/A | |
| Jan 22, 2026 | B of A Securities | Buy | Maintains | $N/A | |
| Jan 12, 2026 | Citigroup | Buy | Maintains | $N/A | |
| Jan 9, 2026 | TD Cowen | Buy | Maintains | $N/A | |
| Jan 9, 2026 | Citigroup | Buy | Maintains | $N/A | |
| Jan 9, 2026 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jan 6, 2026 | Citigroup | Buy | Upgrade | $N/A | |
| Nov 4, 2025 | Citigroup | Neutral | Maintains | $N/A | |
| Nov 4, 2025 | Chardan Capital | Buy | Maintains | $N/A |
Krystal Biotech Inc. (KRYS) Competitors
The following stocks are similar to Krystal Biotech based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
KRYS
Krystal Biotech
mkt cap
9.11B
Krystal Biotech Inc. (KRYS) Financial Data
Krystal Biotech Inc. has a market capitalization of $8.87B with a P/E ratio of 41.1x. The company generates $417.30M in trailing twelve-month revenue with a 53.9% profit margin.
Revenue growth is +31.9% quarter-over-quarter, while maintaining an operating margin of +46.1% and return on equity of +19.9%.
Valuation Metrics
Market Cap
$8.87B
Enterprise Value
$8.26B
P/E Ratio
41.1x
PEG Ratio
0.8x
Price/Sales
21.7x
Growth & Margins
Revenue Growth (YoY)
+31.9%
Gross Margin
+94.6%
Operating Margin
+46.1%
Net Margin
+53.9%
EPS Growth
+56.5%
Financial Health
Cash/Price Ratio
+9.3%
Current Ratio
9.5x
Debt/Equity
0.7x
ROE
+19.9%
ROA
+9.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Krystal Biotech Inc. (KRYS) Business Model
About Krystal Biotech Inc.
What They Do
Develops gene therapy products for dermatological conditions.
Business Model
Krystal Biotech generates revenue by developing and commercializing gene therapy products aimed at treating rare skin diseases. Utilizing its proprietary STAR-D platform, the company focuses on the non-viral delivery of therapeutic genes, addressing unmet medical needs in the dermatological space.
Additional Information
Founded in 2016 and based in Pittsburgh, Pennsylvania, Krystal Biotech is committed to innovative science and improving patient outcomes in the healthcare and biotechnology sectors. The company's focus on genetic skin diseases positions it as a key player in the niche market of gene therapy.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
295
CEO
Mr. Krish S. Krishnan M.B.A., M.S.
Country
United States
IPO Year
2017
Website
www.krystalbio.comKrystal Biotech Inc. (KRYS) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Is the Options Market Predicting a Spike in Krystal Biotech Stock?
Investors need to pay close attention to KRYS stock based on the movements in the options market lately.
Jun 05, 2026
By Zacks Equity Research
Tale of the Tape
Why Is Techne (TECH) Up 4.5% Since Last Earnings Report?
Techne (TECH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Jun 05, 2026
By Zacks Equity Research
Realtime BLOG
Why Is Cytokinetics (CYTK) Down 5.5% Since Last Earnings Report?
Cytokinetics (CYTK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Jun 04, 2026
By Zacks Equity Research
Realtime BLOG
Latest News
Quick Summary
Krystal Biotech (KRYS) reported earnings 30 days ago; investors may want to monitor future developments and stock performance following the earnings announcement.
Why It Matters
Earnings reports can influence stock price movements. Investors will look for guidance on future performance and potential growth, impacting KRYS's market valuation and investment decisions.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Zacks Premium offers Style Scores to help value, growth, and momentum investors identify strong stocks more easily.
Why It Matters
Zacks Style Scores enhance stock selection across investment strategies, potentially increasing returns and minimizing risks, making it a valuable tool for informed decision-making.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Corbus Pharmaceuticals (Nasdaq: CRBP) will hold a conference call and webcast on May 26 at 8:00 a.m. to discuss its oncology and obesity therapies.
Why It Matters
Corbus Pharmaceuticals' upcoming conference call may provide insights into their drug development progress, impacting stock performance and investor sentiment in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Krystal Biotech's VYJUVEK received UK regulatory approval for treating dystrophic epidermolysis bullosa (DEB) from birth, marking it as the first genetic medicine for DEB in the UK.
Why It Matters
Krystal Biotech's VYJUVEK approval in the UK enhances its market position in genetic therapies, potentially increasing revenue and investor confidence due to its innovative treatment for DEB.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Krystal Biotech, Inc. (KRYS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
24 days ago
Quick Summary
Krystal Biotech, Inc. (KRYS) recently presented at the Bank of America Global Healthcare Conference, discussing their developments and future outlook.
Why It Matters
Krystal Biotech's presentation at a major healthcare conference highlights its strategic initiatives and potential pipeline developments, influencing investor sentiment and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
A genetic disorder treatment developer's stock reached a buy point following its first-quarter earnings report last week.
Why It Matters
The stock reaching a buy point post-earnings indicates strong investor confidence and potential for growth, signaling a favorable investment opportunity in the biotech sector.
Source: Investors Business Daily
Market Sentiment:
Positive
Frequently Asked Questions About KRYS Stock
What is Krystal Biotech Inc.'s (KRYS) stock forecast for 2026?
Based on our analysis of 3 Wall Street analysts, Krystal Biotech Inc. (KRYS) has a median price target of $310.00. The highest price target is $399.00 and the lowest is $241.00.
Is KRYS stock a good investment in 2026?
According to current analyst ratings, KRYS has 10 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $301.00. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for KRYS stock?
Wall Street analysts predict KRYS stock could reach $310.00 in the next 12 months. This represents a 3.0% increase from the current price of $301.00. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Krystal Biotech Inc.'s business model?
Krystal Biotech generates revenue by developing and commercializing gene therapy products aimed at treating rare skin diseases. Utilizing its proprietary STAR-D platform, the company focuses on the non-viral delivery of therapeutic genes, addressing unmet medical needs in the dermatological space.
What is the highest forecasted price for KRYS Krystal Biotech Inc.?
The highest price target for KRYS is $399.00 from at , which represents a 32.6% increase from the current price of $301.00.
What is the lowest forecasted price for KRYS Krystal Biotech Inc.?
The lowest price target for KRYS is $241.00 from at , which represents a -19.9% decrease from the current price of $301.00.
What is the overall KRYS consensus from analysts for Krystal Biotech Inc.?
The overall analyst consensus for KRYS is bullish. Out of 3 Wall Street analysts, 10 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $310.00.
How accurate are KRYS stock price projections?
Stock price projections, including those for Krystal Biotech Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 6, 2026 9:26 PM UTC